Impact of Capsular Tension Ring Implantation on Intraocular Lens Position

Sponsor
Xuhua Tan (Other)
Overall Status
Recruiting
CT.gov ID
NCT05161520
Collaborator
(none)
186
1
2
20.5
9.1

Study Details

Study Description

Brief Summary

This is a randomized controlled trial to investigate the effect of capsular tension ring (CTR) implantation on intraocular lens (IOL) tilt and decentration in cataract patients with high myopia.

Condition or Disease Intervention/Treatment Phase
  • Procedure: phacoemulsification combined with IOL and CTR implantation
  • Procedure: phacoemulsification combined with IOL implantation
N/A

Detailed Description

Exact positioning and alignment of the IOL with the visual axis are the prerequisites of high-quality visual performance after cataract surgery. A certain degree of IOL tilt and decentration occur after uneventful cataract surgery, most of which are clinically tolerant. However, the relatively large capsular bag volume, zonular weakness, and vitreous liquefaction in cataract patients with high myopia may increase the IOL position instability, such as tilt, decentration and even dislocation, leading to the deterioration of visual function. Thus, how to improve the long-term stability of IOL position in high myopic cataract patients is an urgent issue to be addressed.

Previous studies have shown that CTR implantation during cataract surgery can increase the IOL stability in patients with normal axial length; however, its impact on IOL position of cataract patients with high myopia remains unclear.

In this randomized clinical trial, patients who meet the inclusion criteria will be divided into three layers according to the axial length:

(1)26mm≤AL<28mm (2)28mm≤AL<30mm (3)AL≥30mm

We are going to recruit 186 patients in total, with 62 patients in each layer. Patients on each layer will be randomly divided into experimental group (CTR implantation) and control group (only IOL implantation). If both eyes of a patient meet the inclusion criteria, only the first operated eye is included in the statistics analysis.

All included patients will be followed up at 1 week, 1 month, 3 months, 6 months, and 1 year postoperatively. Visual acuity, IOL tilt, IOL decentration, posterior capsule attachment with IOL, anterior capsule contraction, posterior capsular opacification, and visual quality will be measured and compared between the experimental group and the control group at different timepoints.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
186 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Impact of Capsular Tension Ring Implantation on Intraocular Lens Tilt and Decentration in Cataract Patients With High Myopia: a Randomized Controlled Trial
Actual Study Start Date :
Dec 16, 2021
Anticipated Primary Completion Date :
Jun 1, 2022
Anticipated Study Completion Date :
Sep 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: IOL plus CTR Patients will undergo phacoemulsification combined with IOL and CTR implantation.

Procedure: phacoemulsification combined with IOL and CTR implantation
Device: CTR (276001G; OPHTEC BV, Netherlands) Device: IOL (920H; Rayner Intracular Lenses Limited,Hove,East Sussex,UK) All patients undergo uneventful phacoemulsification by a 3.0 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, a capsular tension ring is implanted in the capsular bag and then IOL is implanted.

Placebo Comparator: single IOL Patients will undergo phacoemulsification combined with IOL implantation.

Procedure: phacoemulsification combined with IOL implantation
Device: IOL (920H; Rayner Intracular Lenses Limited,Hove,East Sussex,UK) All patients undergo uneventful phacoemulsification by a 3.0 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag.

Outcome Measures

Primary Outcome Measures

  1. IOL dencentration [3 months after surgery]

    Measured by anterior segment OCT (CASIA2)

Secondary Outcome Measures

  1. IOL dencentration [Baseline (before surgery), 1 week, 1 month, 6 months, 1 year after surgery]

    Measured by anterior segment OCT (CASIA2)

  2. IOL tilt [Baseline (before surgery), 1 week, 1 month, 3 months, 6 months, 1 year after surgery]

    Measured by anterior segment OCT (CASIA2)

  3. Anterior capsule contraction [Baseline, 1 week, 1 month, 3 months, 6 months, 1 year after surgery]

    Compare the area of anterior capsule opening recorded by slit lamp photograph and analyzed by Image J software.

  4. Posterior capsule attachment with IOL [1 week, 1 month, 3 months, 6 months, 1 year after surgery]

    Measured by anterior segment OCT (CASIA2) and analyzed by Image J software.

  5. Posterior capsular opacification [1 week, 1 month, 3 months, 6 months, 1 year after surgery]

    Recorded by slit lamp photograph and analyzed by EPCO2000 analysis software.

  6. BCVA [Baseline (before surgery), 1 week, 1 month, 3 months, 6 months, 1 year after surgery]

    BCVA is evaluated with ETDRS visual acuity chart.

  7. Optical quality [Baseline (before surgery), 1 week, 1 month, 3 months, 6 months, 1 year after surgery]

    Measured by OPD-SCAN III.

  8. Visual function [3 months, 6 months, 1 year after surgery]

    Measured by visual function assessment questionnaires.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. 18 years old;

  2. axis length≥26mm;

  3. Visually significant cataract;

  4. The patient is willing and able to complete all necessary follow-ups and examinations.

Exclusion Criteria:
  1. Intraoperative or postoperative complications: such as intraoperative posterior capsular rupture, zonular dehiscence, secondary glaucoma, endophthalmitis, etc.;

  2. Other ocular comorbidity: such as keratopathy, glaucoma, uveitis, retinopathy, lens dislocation and ocular trauma, etc.;

  3. History of intraocular surgery;

  4. Severe systemic diseases: such as severe hypertension, diabetes, heart disease, Alzheimer's, Parkinson, etc.;

  5. Any condition that the study physician considers to be an impediment to the clinical trial.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Zhongshan Ophthalmic Center, Sun Yat-sen University Guangzhou Guangdong China 510060

Sponsors and Collaborators

  • Xuhua Tan

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Xuhua Tan, Associate Professor, Zhongshan Ophthalmic Center, Sun Yat-sen University
ClinicalTrials.gov Identifier:
NCT05161520
Other Study ID Numbers:
  • 2021KYPJ128
First Posted:
Dec 17, 2021
Last Update Posted:
Feb 28, 2022
Last Verified:
Feb 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 28, 2022